Optimal post-remission strategy for patients with acute myeloid leukemia (AML) is matter of intense debate. Recent reports have shown stronger anti-leukemic activity but similar survival for allogeneic stem cell transplantation (allo-HSCT) from matched sibling donor compared to autologous transplantation (auto-HSCT); however, there is scarcity of literature confronting auto-HSCT with allo-HSCT from unrelated donor (UD-HSCT), especially mismatched UD-HSCT.

Saraceni, F., Labopin, M., Gorin, N., Blaise, D., Tabrizi, R., Volin, L., et al. (2016). Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. JOURNAL OF HEMATOLOGY & ONCOLOGY, 9(1), 79 [10.1186/s13045-016-0314-x].

Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT

ARCESE, WILLIAM;
2016-01-01

Abstract

Optimal post-remission strategy for patients with acute myeloid leukemia (AML) is matter of intense debate. Recent reports have shown stronger anti-leukemic activity but similar survival for allogeneic stem cell transplantation (allo-HSCT) from matched sibling donor compared to autologous transplantation (auto-HSCT); however, there is scarcity of literature confronting auto-HSCT with allo-HSCT from unrelated donor (UD-HSCT), especially mismatched UD-HSCT.
2016
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Acute myeloid leukemia (AML); Allogeneic transplantation; Autologous transplantation; Matched (10/10) and mismatched (9/10) unrelated donor transplantation; Post-remission therapy
Saraceni, F., Labopin, M., Gorin, N., Blaise, D., Tabrizi, R., Volin, L., et al. (2016). Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. JOURNAL OF HEMATOLOGY & ONCOLOGY, 9(1), 79 [10.1186/s13045-016-0314-x].
Saraceni, F; Labopin, M; Gorin, N; Blaise, D; Tabrizi, R; Volin, L; Cornelissen, J; Cahn, J; Chevallier, P; Craddock, C; Wu, D; Huynh, A; Arcese, W; Mohty, M; Nagler, A
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/162751
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 33
social impact